{
    "id": "e69b3cad-c7ed-4826-acca-c1472ef51d2b",
    "indications": "sirolimus mtor inhibitor immunosuppressant indicated prophylaxis organ rejection patients aged ≥13 years receiving renal transplants : - patients low- moderate-immunologic risk : initially cyclosporine ( csa ) corticosteroids . csa withdrawal recommended 2–4 months transplantation ( 1.1 ) . - patients high-immunologic risk : combination csa corticosteroids first 12 months following transplantation ( 1.1 ) . safety efficacy csa withdrawal established high risk patients ( 1.1 , 1.2 , 14.3 ) . sirolimus mtor inhibitor indicated treatment patients lymphangioleiomyomatosis ( 1.3 ) .",
    "contraindications": "sirolimus administered orally daily , consistently without food [ ( 2.5 ) , pharmacology ( 12.3 ) ] . tablets crushed , chewed split . patients unable take tablets prescribed solution instructed .",
    "warningsAndPrecautions": "since sirolimus absorbed skin , special . sirolimus expiration date . expiration date refers last day month .",
    "adverseReactions": "sirolimus contraindicated patients hypersensitivity sirolimus [ ( 5.4 ) ] .",
    "ingredients": [
        {
            "name": "SIROLIMUS",
            "code": "W36ZG6FT64"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "CALCIUM SULFATE, UNSPECIFIED FORM",
            "code": "WAT0DDB505"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": ".ALPHA.-TOCOPHEROL ACETATE",
            "code": "9E8X80D2L0"
        },
        {
            "name": "GLYCERYL OLEATE",
            "code": "4PC054V79P"
        }
    ],
    "organization": "Mylan Pharmaceuticals Inc.",
    "name": "Sirolimus",
    "effectiveTime": "20250527",
    "indications_original": "Sirolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants: - Patients at low- to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2–4 months after transplantation ( 1.1 ). - Patients at high-immunologic risk: Use in combination with CsA and corticosteroids for the first 12 months following transplantation ( 1.1 ). Safety and efficacy of CsA withdrawal has not been established in high risk patients ( 1.1 , 1.2 , 14.3 ). Sirolimus is an mTOR inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis ( 1.3 ).",
    "contraindications_original": "Sirolimus is to be administered orally once daily, consistently with or without food [see Dosage and Administration (2.5), Clinical Pharmacology (12.3)\n                     ].\n                  Tablets should not be crushed, chewed or split. Patients unable to take the tablets should be prescribed the solution and instructed in its use.",
    "warningsAndPrecautions_original": "Since sirolimus is not absorbed through the skin, there are no special precautions.\n                  Do not use sirolimus after the expiration date. The expiration date refers to the last day of that month.",
    "adverseReactions_original": "Sirolimus is contraindicated in patients with a hypersensitivity to sirolimus [see Warnings and Precautions (5.4)\n                     ]."
}